Fate Therapeutics, Inc. · NASDAQ:FATE
Fate Therapeutics — Investor Presentation (June 2026)
32 slides from Fate Therapeutics's investor presentation, Jun 4, 2026
Slide 1: Corporate Presentation June 2026
TRANSFORMING THE LIVES OF PATIENTS LIV ING WITH AUTOIMMUN E DISEASES AND C ANCER Making Cell Therapies Accessible to AllTM CORPORATE PRESENTATION June 2026 | NASDAQ: FATE | Non-Confidential © 2026 Fate Therapeutics. All rights reserved
Slide 2: Forward-Looking Statements
Forward-Looking Statements This presentation contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, including statements regarding the safety and therapeutic potential of the Company’s product candidates, the advancement of and plans and tim
Slide 3: Advancing The Frontier of Off-the-Shelf Cell Therapy
Advancing The Frontier of Off-the-Shelf Cell Therapy Progressing a pipeline of novel CAR T-cell therapies to treat autoimmune diseases and cancer COMMENCE PHASE 2 POTENTIALLY DIFFERENTIATED CELL THE RAPY PIPELINE REGISTRATIONAL TR IAL IN SLE WITH LN CREATING PATI ENT & COMMERCIAL VALUE RECLAIM- LN C
Slide 4: A Scalable Platform for Programmable Cellular Therapies
A Scalable Platform for Programmable Cellular Therapies Clonal source + multiplexed engineering = unlimited standardized drug doses at low cost of goods (COGs) Best-In-Class Cell Programming & Engineering Unmatched Scalable Cell Manufacturing Capability • iPSC reprogramming technology based on Nobel
Slide 5: Innovators in Delivering Value & Access to Patients
Innovators in Delivering Value & Access to Patients Resetting the paradigm – not just the patient Unlocking broad patient access to CAR T-cell therapy ENGINEERED FOR SAFETY & ACCESSIBILTY • Precision engineered, clonally derived to manufacture uniform product candidates • Built-in innovative genetic
Slide 6: Off-the-Shelf Cell Therapy Product Pipeline
Off-the-Shelf Cell Therapy Product Pipeline Development of transformative medicines for complex diseases Program CAR/Antigen Target Indication Pre Clinical Phase 1/2 Registrational Partner Autoimmunity FT819-201 (RECLAIM- LN) NCT07570862 Lupus Nephritis (LN) (RMAT) Not Yet Enrolling Systemic Lupus E
Slide 7: Addressing Diseases with Significant Unmet Clinical Need
Addressing Diseases with Significant Unmet Clinical Need Broad patient accessibility with on-demand off-the-shelf CAR T-cell therapies Autoimmune Disease Oncology Anti-neutrophil cytoplasmic auto- Idiopathic Systemic Lupus Systemic antibody Inflammatory Hematological Erythematosus Sclerosis Solid Tu
Slide 8: FT819: Anti-CD19 CAR T-Cell Product Candidate
PHASE 1 CLINICAL TRIAL UPDATE & PHASE 2 RECLAIM-LN FT819 Making Cell Therapy Accessible to All 8 FT819: Anti-CD19 CAR T-Cell Product Candidate Safe and effective targeting of CD19+ B cells with broad patient accessibility Lead Clinical Asset Derived from a defined clonal MCB incorporating True Off-t
Slide 9: FT819 in Autoimmune Diseases – Phase 1 (FT819-102) Update
FT819 in Autoimmune Diseases – Phase 1 (FT819-102) Update Uniquely administered with less-intensive fludarabine-free or no conditioning chemotherapy Conditioning chemotherapy Conditioning Treatment Cycle / DLT Assessment PTFU LTFU Day FT819 infusion Study Day: -5 -4 -3 1 2 4 8 15 22 29 Cyclophospham
Slide 10: FT819 Baseline characteristics of patients with SLE
FT819 in Autoimmune Diseases – Phase 1 (FT819-102) Update Baseline characteristics of patients with SLE treated with FT819 FT819-102 SLE Patient Cohort Representative of Real-World Patient Characteristics1,2 Essential Patient Features Baseline Patient Parameters Regimen A (N=16)1,2 Age, y, mean (ran
Slide 11: FT819 Preliminary Safety Data in SLE
FT819 in Autoimmune Diseases – Phase 1 (FT819-102) Update All Regimen A patients with SLE tolerated FT819 without DLT, no grade >2 CRS, ICANS, GvHD or deaths reported on study Preliminary Safety Data of FT819 in Regimen A SLE; Select AESIs1-2 Safety data in line with FT819-101 in B cell malignancies
Slide 12: FT819 Rapid and Sustained Clinical Improvement
FT819 in Autoimmune Diseases – Phase 1 (FT819-102) Update FT819 with less intensive conditioning demonstrates rapid and sustained clinical improvement Disease activity measures among patients with SLE in Regimen A with at least 1 Month follow-up1-2 UPCr cSLEDAI-2K Score PGA Score FACIT-Fatigue 4 16
Slide 13: FT819 with Bendamustine Drives Deep B Cell Depletion
FT819 in Autoimmune Diseases – Phase 1 (FT819-102) Update FT819 with bendamustine cooperate to drive deep B cell depletion and B cell compartment remodeling FT819 elicits deep B cell depletion and immune reconstitution absent of pre-existing dominant B cell clones1,2 KEY TAKEAWAYS FT819 + Cyclophosp
Slide 14: FT819 B Cell Reconstitution Dominated by Naïve State
FT819 in Autoimmune Diseases – Phase 1 (FT819-102) Update FT819 with bendamustine cooperate to drive deep B cell depletion and B cell compartment remodeling FT819 mediated B cell reconstitution is dominated by naïve state subsets with pre-existing vaccine immunity maintained1,2 BCR Remodeling Toward
Slide 15: RECLAIM-LN: A Phase 2 Potentially Registrational Trial in Lupus Nephritis
RECLAIM-LN: A Phase 2 Potentially Registrational Trial in Lupus Nephritis FT819-201 (RECLAIM-LN) patient enrollment planned to commence in 2H2026 OPEN LABEL, SINGLE ARM STUDY FOR PATIENTS WITH REFRACTORY MODERATE-TO-SEVERE SLE WITH LN1,2 RECLAIM-LN Trial Schema ✓ Single d ose of 900M cells ✓ Less-in
Slide 16: FT819-102 Regimen B Cohort – No Conditioning Therapy Update
FT819-102 Regimen B Cohort – No Conditioning Therapy Update Preliminary data highlights FT819 single agent activity without any conditioning chemotherapy Sustained clinical response achieved by low dose FT819 in the absence of conditioning chemotherapy1,2 B Cell Depletion with/or without Improved Fa
Slide 17: Next Generation Cell Therapy Franchise
NEXT GENERATION CELL THERAPY FRANCHISE Making Cell Therapy Accessible to All 18
Slide 18: FT836: Off-the-Shelf Anti-MICA/B CAR T Cell Product Candidate
FT836: Off-the-Shelf Anti-MICA/B CAR T Cell Product Candidate Next-gen ADR-armed CAR T cell targets stress ligands MICA/B to eliminate a broad spectrum of tumors True Off-the-Shelf Next Generation Multi-Antigen Targeting CAR T Cell Drug Product Product Candidate Engineered Attribute Systems • MICA/B
Slide 19: Targeting MICA/B Overcomes Tumor Evasion & Unlocks Pan-Tumor Potential
Targeting MICA/B Overcomes Tumor Evasion & Unlocks Pan-Tumor Potential Stress-ligand recognition of diseased cell states supports indication-agnostic therapy Novel recognition of MICA/B á3 domain MICA/B shedding is a common immune MICA/B is widely expressed unlocks pan-tumor recognition1,2 evasion m
Slide 20: Phase 1 FT836-101 Study in Pan Solid Tumor Now Enrolling
Phase 1 FT836-101 Study in Pan Solid Tumor Now Enrolling Evaluation of FT836 with/without monoclonal antibody combination & optional tumor priming therapy 1 Highly-Differentiated FT836 Clinical Study Schema 1 Therapeutic Approach ➢ Novel cancer antigen targeting system that u niquely Phase 1 Study D
Slide 21: FT836 Baseline Characteristics and Adverse Events
Phase 1 FT836-101 Study in Pan Solid Tumor Now Enrolling Fate THERAPEUTICS Baseline characteristics and adverse events by regimen in patients treated with FT836 without conditioning chemotherapy Baseline Characteristics1,2 Adverse Events of Interest by Regimen, Any Grade & Grade >3 1,2 Regimen C: Re
Slide 22: Preliminary Anti-Tumor Activity in KRAS Wild-Type CRC
Phase 1 FT836-101 Study in Pan Solid Tumor Now Enrolling Preliminary anti-tumor activity observed in KRAS wild-type colorectal cancer (CRC) patients CLINICAL CASE 11,2 CLINICAL CASE 2 1,2 • 45/M with metastatic CRC, KRAS wild-type (KRASWT) • 53/M with metastatic CRC, KRASWT • 7 prior lines of therap
Slide 23: FT836 Tumor Tissue Trafficking and Functional Persistence
Phase 1 FT836-101 Study in Pan Solid Tumor Now Enrolling FT836 demonstrated tumor tissue trafficking and functional persistence in the absence of conditioning chemotherapy FT836 persistence in the periphery and tumor Redistribution of CD8 cells in tumor tissue post infusion tissue post infusion FT83
Slide 24: FT839: Off-the-Shelf Anti-CD19/Anti-CD38 CAR T Cell Product Candidate
FT839: Off-the-Shelf Anti-CD19/Anti-CD38 CAR T Cell Product Candidate Next-Gen Sword & ShieldTM empowered T cell targeting select immune cell subsets to unlock multi-disease therapy potential True Off-the-Shelf Next Generation Product Candidate Engineered Attribute Systems Multi-Antigen Targeting CA
Slide 25: FT839 Broadly & Selectively Eliminates Aberrant Immune Cells
FT839 Broadly & Selectively Eliminates Aberrant Immune Cells Targeting CD19 & CD38 selectively eliminates B lineage cells and activated state immune cells FT839 targets multiple aberrant immune cell types that drive autoimmune & hematological malignant diseases CD19/CD38 dual targeting addresses the
Slide 26: Off-the-Shelf CAR T-Cell and CAR NK-Cell Product Candidates
Off-the-Shelf CAR T-Cell and CAR NK-Cell Product Candidates Our broader product pipeline holds significant value opportunities in oncology & autoimmune disease FT825/ONO-8250: Multi-Antigen Targeting CD19 CAR NK Cell Off-the-shelf anti-HER2 CAR T-cell product candidate with ADR enabled to reduce/eli
Slide 27: Best-in-Class Allo-Immune Evasion Systems Enhance Persistence
Best-in-Class Allo-Immune Evasion Systems Enhance Persistence for a Comprehensive Approach to Cell Therapy and Regenerative Medicine Unique ability to overcome the need for conditioning chemotherapy backed by clinical data Next Generation CAR T-Cell Products Regenerative Medicine Products Sword & Sh
Slide 28: Finance & Business Updates
FINANCE & BUSINESS UPDATES Making Cell Therapy Accessible to All 29
Slide 29: Q1 2026 Financial Snapshot
Q1 2026 Financial Snapshot Strong Balance Sheet and Financial Discipline CASH & SHORT-TERM WEIGHTED-AVG SHARES CASH RUNWAY INVESTMENTS OUTSTANDING $174.8M Into 2028 120.0M EXPENSE BREAKDOWN ($ THOUSANDS) Q1 YoY EXP ENSE SAVINGS Q1 2025 Q1 2026 42,909 $8.6M 34,2 99 29,136 24,703 Total quarterly savin
Slide 30: Business Updates & Near-Term Objectives
Business Updates & Near-Term Objectives Competitively positioned to accelerate clinical stage development Milestones Achieved Near Term Next Steps ✓ Treatment of 22 patients with SLE, and 8 across SSc, Complete Phase 1 SLE cohort enrollment in LN subset IIM and AAV; 21 activated clinical sites1 Eval
Slide 31: Business Updates & Near-Term Objectives
Business Updates & Near-Term Objectives Fcte Competitively positioned to accelerate clinical stage development Milestones Achieved Near Term Next Steps v Treatment of 22 patients with SLE, and 8 across SSc, Complete Phase 1 SLE cohort enrollment in LN subset IIM and AAV; 21 activated clinical sites?
Slide 32: Making Cell Therapies Accessible to All
Making Cell Therapies Accessible to AllTM June 2026 © 2026 Fate Therapeutics. All rights reserved www.fatetherapeutics.com
Fate Therapeutics — Investor Presentation (June 2026) on 6ix